The MCT rat model of PAH was used to evaluate the chronic efficacy of once daily WT BMP9 administration at multiple dose levels (3–100 μg/kg, SC) delivered in a disease prevention study initiating treatment at the same day as MCT dosing. Here, GDF2 is linked to pulmonary arterial hypertension.